PHOTO
Production of China’s Sinopharm vaccine in the UAE will begin next month, according to Bloomberg.
Gulf Pharmaceutical Industries PSC (also known as Julphar) said on Sunday that it had signed a contract to start manufacturing the vaccine from April onwards, Bloomberg said in its report.
According to the Bloomberg report, Julphar said it has entered a contract manufacturing agreement with Abu Dhabi’s G42 Medications Trading.
G42 is an artificial intelligence and cloud computing company that has lead the clinical trial operations of Sinopharm in the UAE under the supervision of the Department of Health of Abu Dhabi.
With this deal, the UAE will become the first GCC state to set up a coronavirus vaccine production facility, with the objective of supplying the vaccine both to the Middle East and beyond.
The Dubai Health Authority (DHA) began providing the Sinopharm COVID-19 vaccine to Emirati citizens and Dubai residents who are 60 and over from 31 January 2021. The UAE has also approved vaccines from Pfizer Inc. and AstraZeneca Plc as well as Russia’s Sputnik V.
(Writing by Seban Scaria; editing by Daniel Luiz)
Disclaimer: This article is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Read our full disclaimer policy here.
© ZAWYA 2021
